Collplant Biotechnologies Ltd (CLGN) - Total Assets
Based on the latest financial reports, Collplant Biotechnologies Ltd (CLGN) holds total assets worth $14.09 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Collplant Biotechnologies Ltd net assets for net asset value and shareholders' equity analysis.
Collplant Biotechnologies Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Collplant Biotechnologies Ltd's total assets have evolved over time, based on quarterly financial data.
Collplant Biotechnologies Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Collplant Biotechnologies Ltd's total assets of $14.09 Million consist of 70.4% current assets and 29.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 63.7% |
| Accounts Receivable | $583.00K | 3.1% |
| Inventory | $440.00K | 2.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $131.00K | 0.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Collplant Biotechnologies Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Collplant Biotechnologies Ltd (CLGN) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Collplant Biotechnologies Ltd's current assets represent 70.4% of total assets in 2024, a decrease from 71.4% in 2012.
- Cash Position: Cash and equivalents constituted 63.7% of total assets in 2024, up from 55.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 9.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 3.1% of total assets.
Collplant Biotechnologies Ltd Competitors by Total Assets
Key competitors of Collplant Biotechnologies Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Collplant Biotechnologies Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.66 | 5.38 | 1.68 |
| Quick Ratio | 3.45 | 5.23 | 1.30 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $6.99 Million | $13.43 Million | $2.29 Million |
Collplant Biotechnologies Ltd - Advanced Valuation Insights
This section examines the relationship between Collplant Biotechnologies Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.93 |
| Latest Market Cap to Assets Ratio | 0.28 |
| Asset Growth Rate (YoY) | -45.2% |
| Total Assets | $18.71 Million |
| Market Capitalization | $5.26 Million USD |
Valuation Analysis
Below Book Valuation: The market values Collplant Biotechnologies Ltd's assets below their book value (0.28x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Collplant Biotechnologies Ltd's assets decreased by 45.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Collplant Biotechnologies Ltd (2012–2024)
The table below shows the annual total assets of Collplant Biotechnologies Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $18.71 Million | -45.17% |
| 2023-12-31 | $34.13 Million | -9.64% |
| 2022-12-31 | $37.77 Million | -26.27% |
| 2021-12-31 | $51.22 Million | +372.50% |
| 2020-12-31 | $10.84 Million | +0.83% |
| 2019-12-31 | $10.75 Million | +18.81% |
| 2018-12-31 | $9.05 Million | +12.15% |
| 2017-12-31 | $8.07 Million | +115.05% |
| 2016-12-31 | $3.75 Million | +8.26% |
| 2015-12-31 | $3.47 Million | -20.42% |
| 2014-12-31 | $4.35 Million | -49.90% |
| 2013-12-31 | $8.69 Million | +73.81% |
| 2012-12-31 | $5.00 Million | -- |
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more